Mercy BioAnalytics, Inc.

About

Mercy BioAnalytics, Inc. is a biotechnology company based in Natick, Massachusetts, founded in 2018. The company is dedicated to early cancer detection through its proprietary Mercy Halo™ liquid biopsy platform. This platform analyzes tumor-derived extracellular vesicles (EVs) in blood to identify cancers such as ovarian and lung at treatable stages. Mercy BioAnalytics develops accurate, low-cost blood tests that utilize abundant EVs, which carry cancer-specific signatures. The Mercy Halo™ platform employs qPCR technology to detect cancer-associated biomarkers on single EVs, enabling sensitive and specific early detection. The company has demonstrated strong performance in clinical studies, with its tests showing high sensitivity and specificity for ovarian and lung cancers. Mercy's mission is to reduce suffering by detecting hard-to-screen cancers early, supported by a team of experts in cancer diagnostics and ongoing collaborations with research institutions.